Search Results

GeNeuro, a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases, announced a collaboration with Verily, an Alphabet precision health technology company, to investigate biomarkers related to activation of the proinflammatory HERV-W envelope protein in SARS-CoV-2 infection.

GeNeuro (Euronext Paris: CH0308403085 - GNRO), announced today the joint publications in the leading scientific journal “Annals of Neurology” of the results of the collaboration between GeNeuro and the National Institute of Neurological Disorders and Stroke (NINDS). NINDS is part of the National Institutes of Health (NIH) of the United States.

GeNeuro announced the recruitment of first patients in its Phase 2 trial evaluating temelimab against long-COVID at the Geneva University Hospitals post-COVID clinic, as well as in all the other Swiss clinical centres participating to the study, i.e., Inselspital in Bern, REHAB Basel, Kantonsspital Graubünden in Chur and the Centre Hospitalier du Valais Romand in Sion.

Research aims to confirm evidence of the expression of human endogenous retrovirus W envelope protein (HERV-W ENV or W-ENV) in long-haul COVID patients, and identify affected patients who may benefit from a treatment with GeNeuro’s temelimab.

GeNeuro announced that its development in Long-COVID is one of the four projects selected by the Swiss Federal Office of Public Health and that it will receive in this regard a grant of 6.7 million Swiss francs to co-fund a Phase 2 clinical trial to treat patients with long-standing COVID who exhibit severe neurological and psychiatric symptoms.

There are several approaches on the horizon in ALS, a space that is gaining momentum. BioSpace spoke with GeNeuro, NeuroSense and the Tisch MS Research Center about their progress.

GeNeuro is developing therapeutics that tackle the viral proteins that potentially contribute to neurodegeneration seen in patients with MS, amyotrophic lateral sclerosis (ALS) and even COVID-19.